Lixte Biotechnology Holdings Accounts Payables 2011-2026 | LIXT

Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.

Main types of accounts payable

Type of liability	Example
To suppliers and contractors	Goods received but not yet paid for
Taxes and fees	VAT, income tax, etc., not paid on time
Salaries	Employee wages not paid
To budgets	Insurance contributions to funds not paid
To founders	Founders provided borrowed funds
To banks	Overdue loan payments
Other	Fines, penalties, forfeits, customer prepayments, etc.

Impact on the company's financial performance

Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios
Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence
Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals)
Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated

Quarterly Accounts Payables Lixte Biotechnology Holdings

2025-Q3	2025-Q2	2024-Q4	2024-Q3	2024-Q2	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	45 K	47 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
47 K	45 K	46 K

Accounts Payables of other stocks in the Biotechnology industry

Issuer	Accounts Payables	Price	% 24h	Market Cap	Country
AgeX Therapeutics AGE	1.93 M	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	570 M	-	-	$ 866 M	China
Esperion Therapeutics ESPR	65.1 M	$ 3.13	0.55 %	$ 651 M	USA
Exelixis EXEL	29.6 M	$ 48.2	8.51 %	$ 13.1 B	USA
Fortress Biotech FBIO	14.2 M	$ 2.53	2.85 %	$ 70.6 M	USA
Athira Pharma ATHA	4.59 M	-	-	$ 269 M	USA
Ionis Pharmaceuticals IONS	28.1 M	$ 77.0	2.33 %	$ 12.3 B	USA
Checkmate Pharmaceuticals CMPI	3.38 M	-	-	$ 231 M	USA
Kymera Therapeutics KYMR	4.02 M	$ 85.79	3.72 %	$ 7.25 B	USA
Ligand Pharmaceuticals Incorporated LGND	5.23 M	$ 231.58	-0.31 %	$ 4.24 B	USA
INmune Bio INMB	199 K	$ 1.54	-	$ 38.1 M	USA
Liquidia Corporation LQDA	3.68 M	$ 41.64	3.75 %	$ 3.58 B	USA
ACADIA Pharmaceuticals ACAD	16.2 M	$ 22.58	1.03 %	$ 3.74 B	USA
Mirum Pharmaceuticals MIRM	9.61 M	$ 107.36	1.46 %	$ 5.39 B	USA
MannKind Corporation MNKD	9.03 M	$ 3.61	26.17 %	$ 1.1 B	USA
Advaxis ADXS	6.08 M	-	-9.65 %	$ 45.9 M	USA
Can-Fite BioPharma Ltd. CANF	561 K	$ 3.46	-1.14 %	$ 5.7 M	Israel
Aeglea BioTherapeutics AGLE	677 K	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.91 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	611 K	-	1.93 %	$ 17.4 M	USA
Akero Therapeutics AKRO	9.03 M	-	-	$ 3.67 B	USA
Aptose Biosciences APTO	2.91 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	724 K	-	-39.0 %	$ 4.57 M	USA
Akouos AKUS	1.28 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	6.52 M	-	-0.23 %	$ 916 M	USA
Allakos ALLK	1.76 M	-	-	$ 28.6 M	USA
AlloVir ALVR	1.28 M	-	4.14 %	$ 49.1 M	USA
Arcutis Biotherapeutics ARQT	12.5 M	$ 24.0	2.46 %	$ 3.05 B	USA
Allena Pharmaceuticals ALNA	1.03 M	-	3.16 %	$ 1.9 M	USA
Ampio Pharmaceuticals AMPE	750 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	1.58 M	-	-	$ 10.1 M	USA
Alpine Immune Sciences ALPN	4.29 M	-	-	$ 2.17 B	USA